Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07BIK
|
||||
| Former ID |
DIB016422
|
||||
| Drug Name |
VEL-0230
|
||||
| Synonyms |
NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Phase 1 | [1] | ||
| Company |
Nippon Chemiphar Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H24NNaO5
|
||||
| Canonical SMILES |
O1[C@@H]([C@H]1C(=O)N[C@@H](CC(C)C)COCC(C)C)C(=O)[O-].[<br />Na+]
|
||||
| CAS Number |
CAS 221144-20-3
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
| REF 1 | Velcura Therapeutics, Inc. to Begin Clinical Trials in Rheumatoid Arthritis Patients. Velcura Therapeutics, Inc. JANUARY 07, 2009. | ||||
| REF 2 | Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.